Injectable scaffold for treatment of intracranial aneurysms and related technology

Patent metadata

Field	Value
Publication number	US-12364708-B2
Application number	US-202318483809-A
Country	US
Kind code	B2
Filing date	Oct 10, 2023
Priority date	Oct 21, 2016
Publication date	Jul 22, 2025
Grant date	Jul 22, 2025

Abstract

A method for treating an aneurysm in accordance with a particular embodiment of the present technology includes intravascularly delivering a mixture including a biopolymer (e.g., chitosan) and a chemical crosslinking agent (e.g., genipin) to an aneurysm. The method further includes mixing the biopolymer and the chemical crosslinking agent to initiate chemical crosslinking of the biopolymer. The mixture is delivered to the aneurysm via a lumen and an exit port of a catheter while the chemical crosslinking is ongoing. The mixture exits the catheter as a single cohesive strand that at least partially agglomerates to form a mass occupying at least 75% of a total internal volume of the aneurysm. During delivery of the mixture, the method includes expanding a tubular flow diverter to reinforce a neck of the aneurysm.

First claim

We claim:

1. A system for treating an aneurysm, the system comprising:
a catheter comprising an elongate lumen and an exit port at a distal portion of the elongate lumen; and
a composition comprising a mixture of a biopolymer, a chemical crosslinking agent, and a physical crosslinking agent, wherein the mixture is configured to be delivered into an internal volume of the aneurysm via the elongate lumen and exit port of the catheter, and wherein the mixture is configured to be delivered as a cohesive strand and to at least partially agglomerate to form a mass within the internal volume.

2. The system of claim 1 , wherein the biopolymer comprises chitosan or a derivative or an analog thereof.

3. The system of claim 1 , wherein the chemical crosslinking agent comprises genipin or a derivative or an analog thereof.

4. The system of claim 1 , wherein the physical crosslinking agent comprises β-glycerophosphate or a derivative or an analog thereof.

5. The system of claim 1 , wherein the mixture further comprises a contrast agent.

6. The system of claim 5 , wherein the contrast agent comprises iohexol or a derivative or an analog thereof.

7. The system of claim 1 , further comprising a syringe configured to deliver the mixture into the elongate lumen of the catheter.

8. The system of claim 7 , wherein the syringe is configured to withstand a pressure of at least 500 psi to move the mixture through the elongate lumen to the internal volume of the aneurysm.

9. The system of claim 1 , further comprising an intrasaccular device configured to be implanted into the internal volume of the aneurysm.

10. The system of claim 1 , wherein a size of the elongate lumen is no greater than 3 French.

11. A system for treating an aneurysm, the system comprising:
an elongate member comprising a lumen and a distal end portion configured to be positioned within an aneurysm; and
an injectable material comprising a biopolymer, and a chemical crosslinking agent, and a physical crosslinking agent, wherein the injectable material is configured to be delivered into the aneurysm via the lumen of the elongate member, and wherein the injectable material is configured to be delivered as a cohesive strand and to at least partially agglomerate to form a mass within the aneurysm.

12. The system of claim 11 , wherein the biopolymer comprises chitosan or a derivative or an analog thereof.

13. The system of claim 11 , wherein the chemical crosslinking agent comprises genipin or a derivative or an analog thereof.

14. The system of claim 11 , wherein the physical crosslinking agent comprises β-glycerophosphate or a derivative or an analog thereof.

15. The system of claim 11 , wherein the injectable material further comprises a contrast agent.

16. The system of claim 15 , wherein the contrast agent comprises iohexol or a derivative or an analog thereof.

17. The system of claim 11 , further comprising a syringe configured to deliver injectable material into the lumen of the elongate member.

18. The system of claim 17 , wherein the syringe is configured to withstand a pressure of at least 500 psi to move the injectable material through the lumen to the aneurysm.

19. The system of claim 11 , further comprising an intrasaccular device configured to be implanted into the aneurysm.

20. The system of claim 11 , wherein a size of the lumen of the elongate member is no greater than 3 French.

Assignees

• Covidien Lp

Inventors

• Li Junwei
• Girdhar Gaurav
• Wainwright John
• Bayon Yves
• Pagani Ariana

Classifications

• A61M2210/0687

  Skull, cranium · CPC title

• A61M25/10

  Balloon catheters ({A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02;} inflatable balloons for placing stents or stent-grafts A61F2/958 {; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00}) · CPC title

• A61M5/1452

  pressurised by means of pistons · CPC title

• A61L2400/06

  Flowable or injectable implant compositions · CPC title

• A61L31/042

  Polysaccharides · CPC title